Wills Hughes-Wilson

Corporate Officer/Principal bei MEREO BIOPHARMA GROUP PLC

Vermögen: 860 $ am 30.04.2024

53 Jahre

Health Technology

Consumer Services

Aktive Positionen von Wills Hughes-Wilson

Unternehmen	Position	Beginn	Ende
MEREO BIOPHARMA GROUP PLC	Corporate Officer/Principal	01.03.2018	-

Unternehmen	Position	Beginn	Ende
SWEDISH ORPHAN BIOVITRUM AB	Public Communications Contact	04.07.2012	01.01.2018
	General Counsel	01.02.2012	04.07.2012
	Corporate Officer/Principal	01.02.2012	01.01.2018
Genzyme Therapeutics Ltd. Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.	Corporate Officer/Principal	-	-
European Biopharmaceutical Enterprises European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.	Direktor/Vorstandsmitglied	-	-
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-	-

University of Durham

Graduate Degree

International

Operativ

Corporate Officer/Principal	4
Public Communications Contact	1
General Counsel	1

Sektoral

Health Technology	6
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
MEREO BIOPHARMA GROUP PLC	Health Technology

Private Unternehmen	3
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
European Biopharmaceutical Enterprises European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.	Health Technology
Genzyme Therapeutics Ltd. Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.	Health Technology